Mallinckrodt PLC is looking at the possibility of a sale of its generic drug unit, Reuters reported May 30, citing "people familiar with the matter."

A deal for the unit might be valued at about $2 billion. There is no guarantee the talks will lead to a deal, according to the sources.

The company has reportedly appointed Credit Suisse Group AG to run a sale process for the business.